Join Growin Stock Community!

Cue biopharma, inc.CUE.US Overview

US StockHealthcare
(No presentation for CUE)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CUE AI Insights

CUE Overall Performance

CUE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CUE Recent Performance

0.07%

Cue biopharma, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CUE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CUE Key Information

CUE Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CUE Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Price of CUE

CUE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CUE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.48
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.60
PB Ratio
1.98
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-530.75%
Revenue Growth (YoY)
-25.51%
Profit Growth (YoY)
-25.51%
3-Year Revenue Growth
216.16%
3-Year Profit Growth
216.16%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.48
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.60
PB Ratio
1.98
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-530.75%
Revenue Growth (YoY)
-25.51%
Profit Growth (YoY)
-25.51%
3-Year Revenue Growth
216.16%
3-Year Profit Growth
216.16%

  • When is CUE's latest earnings report released?

    The most recent financial report for Cue biopharma, inc. (CUE) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CUE's short-term business performance and financial health. For the latest updates on CUE's earnings releases, visit this page regularly.

  • What is the operating profit of CUE?

    According to the latest financial report, Cue biopharma, inc. (CUE) reported an Operating Profit of -7.6M with an Operating Margin of -353.42% this period, representing a growth of 13.84% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CUE's revenue growth?

    In the latest financial report, Cue biopharma, inc. (CUE) announced revenue of 2.15M, with a Year-Over-Year growth rate of -35.58%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CUE have?

    As of the end of the reporting period, Cue biopharma, inc. (CUE) had total debt of 6.17M, with a debt ratio of 0.2. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CUE have?

    At the end of the period, Cue biopharma, inc. (CUE) held Total Cash and Cash Equivalents of 12.52M, accounting for 0.4 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CUE go with three margins increasing?

    In the latest report, Cue biopharma, inc. (CUE) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -353.42%%, and net margin of -346.6%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CUE's profit trajectory and future growth potential.

  • Is CUE's EPS continuing to grow?

    According to the past four quarterly reports, Cue biopharma, inc. (CUE)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CUE?

    Cue biopharma, inc. (CUE)'s Free Cash Flow (FCF) for the period is -9M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 21.2% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.